A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

This study is testing loncastuximab tesirine — an antibody-drug conjugate (ADC) that targets CD19 on lymphoma cells — as a consolidation strategy for people with large B-cell lymphoma who had a partial response (but not complete remission) after CAR T-cell therapy. The goal is to deepen the response and prevent relapse. **You may be eligible if...** - You have diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, or transformed indolent lymphoma - You received standard CAR T-cell therapy and achieved a partial response (not complete remission) - Your overall health is adequate for further treatment **You may NOT be eligible if...** - You achieved a complete response after CAR T-cell therapy (you would not need consolidation) - Your disease progressed after CAR T-cell therapy - You have active infection, serious organ problems, or active autoimmune disease Talk to your doctor to see if this trial is right for you.